SMP-190 is under clinical development by Xiling Lab and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SMP-190’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SMP-190 is under development for the treatment of unspecified cancer. The therapeutic candidate is an antibody drug conjugate attached to a topoisomerase I inhibitor payload (Dxd), an exatecan derivative. It is being developed based on Innovative Coupled Drug Platform.
Xiling Lab overview
Xiling Lab is a biopharmaceutical company engaged in research and development based on catalytic synthesis technology to offer novel generic drugs for the treatment of various diseases. The company is headquartered in Chengdu, Sichuan, China.
For a complete picture of SMP-190’s drug-specific PTSR and LoA scores, buy the report here.